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Abstract
Background: Uganda has one of the highest total fertility rates (TFR) worldwide. We compared the effects of antiretroviral
(ARV) prophylaxis for the prevention of mother-to-child HIV transmission (PMTCT) to that of existing family planning (FP)
use and estimated the burden of pediatric HIV disease due to unwanted fertility.
Methodology/Principal Findings: Using the demographic software Spectrum, a baseline mathematical projection to
estimate the current pediatric HIV burden in Uganda was compared to three hypothetical projections: 1) without ARV-
PMTCT (to estimate the effect of ARV-PMTCT), 2) without contraception (effect of existing FP use), 3) without unwanted
fertility (effect of unmet FP needs). Key input parameters included HIV prevalence, ARV-PMTCT uptake, MTCT probabilities,
and TFR. We estimate that in 2007, an estimated 25,000 vertical infections and 17,000 pediatric AIDS deaths occurred
(baseline projection). Existing ARV-PMTCT likely averted 8.1% of infections and 8.5% of deaths. FP use likely averted 19.7% of
infections and 13.1% of deaths. Unwanted fertility accounted for 21.3% of infections and 13.4% of deaths. During 2008–
2012, an estimated 131,000 vertical infections and 71,000 pediatric AIDS deaths will occur. The projected scale up of ARV-
PMTCT (from 39%–57%) may avert 18.1% of infections and 24.5% of deaths. Projected FP use may avert 21.6% of infections
and 18.5% of deaths. Unwanted fertility will account for 24.5% of infections and 19.8% of deaths.
Conclusions: Existing FP use contributes as much or more than ARV-PMTCT in mitigating pediatric HIV in Uganda.
Expanding FP services can substantially contribute towards PMTCT.
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Introduction
Mother-to-child HIV transmission (MTCT) is the second largest
mode of HIV transmission worldwide, accounting for some
370,000 infections in 2007 [1]. Most of these infections occur in
the developing world, particularly in sub-Saharan Africa, where
the prevention of mother-to-child transmission (PMTCT) remains
a promising, yet complex and challenging programmatic under-
taking. In 2007, uptake for antiretrovirals for PMTCT (ARV-
PMTCT) reached 33% in sub-Saharan Africa [2]. In many
countries PMTCT programs focus on antenatal HIV testing,
provision of ARV prophylaxis to HIV-infected women and their
newborns, and counseling on safer infant feeding practices.
However, these three components constitute just one of four
pillars for PMTCT; the remaining being primary HIV prevention
in women of child-bearing age, family planning (FP) for the
prevention of unwanted pregnancies, as well as care and treatment
for HIV-infected women [3] and their HIV-affected children [4].
In Uganda, the HIV epidemic continues to exert a high toll on
children. Uganda’s goal for 2012 is to reduce MTCT of HIV by 50%
[5]. The high burden of pediatric HIV disease, estimated at 120,000–
150,000 children living with HIV/AIDS in 2007 [6], stems from a
7.5% HIV prevalence among adult women aged 15–49 years [7] as
well as from a relatively low ARV uptake estimated at 39% among
HIV-infected ante-natal clinic attendees and 18% among HIV-
exposed newborns[8]. Ugandan women, however, also have very
high fertility accompanied by a low contraceptive prevalence rate
(CPR, estimated at 19.6% [9] among women aged 15–49 years),
fueling a population growth estimated at 3.2% annually [10].
Uganda’s total population grew from 11 million in 1975 to 24 million
in 2000 and is projected to reach 53 million in 2025.[10] Part of this
high fertility is due to unintended pregnancies, which, if occurring in
HIV-positive women, contribute to thousands of pediatric HIV-
infections. Reynolds et al. [11] estimated that more than 7,000
vertical HIV infections in Uganda are averted annually by current
contraceptive use. Not surprisingly, strengthening FP as a component
of PMTCT [12] has recently received more attention [11,13–15].
In this analysis we used demographic projections to compare
the effects of present and projected ARV-prophylaxis and FP use
on decreasing the burden of pediatric HIV disease in Uganda, and
the contribution of continued unwanted fertility on this burden.
Methods
Data sources
The main data sources used for this analysis included the 2006
Demographic and Health Survey [9], the 2004/5 Uganda HIV
Sero-Behavioral Survey (UHSBS) [7], and United Nations reports
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(UN Population Division [10]). We adopted the adult HIV
prevalence estimates by the MOH which was generated with the
Estimation and Projection Package [16] software. Most input data
for this prevalence estimate originated from the ante-natal clinic
based HIV surveillance system; the resulting curve was then
calibrated by the 2004/5 UHSBS-based HIV prevalence estimate
(all adults: 6.4%, females: 7.5%, males: 5.0%). Because the MoH
had not released a new national HIV prevalence estimate at the
time of this analysis, we assumed the 2005 HIV prevalence to
remain constant through 2012. For the ARV uptake for PMTCT
(defined as a nationally approved ARV regimen for PMTCT) we
used program data to estimate uptake until 2008, when uptake
reached 39%. For the years 2009–2012, Uganda has a national
PMTCT uptake goal of 80% [5]; however, existing program data
and funding environment suggest that this target will not be
achievable. Hence the authors adopted a more modest but
achievable increase of 4% (absolute) among HIV-infected pregnant
women per year in ARV-PMTCT uptake from 2009 to 2012,
translating into an ARV-uptake of 57% among ante-natal clinic
attendees by 2012. This modest proportional increase nevertheless
translates into large increases in absolute numbers, from an
estimated 26,600 HIV-infected women receiving ARV-PMTCT
in 2007 to 59,500 in 2012. Following national policy goals, we also
phased out gradually the use of single dose Nevirapine by assuming
that combination ARVs will make up 83% of all ARV regimens by
2010 and 100% by 2012. DHS data suggests a mean breastfeeding
duration of 21 months [9]. Other key input parameters such as
MTCT probabilities by ARV prophylaxis regimen and infant
feeding mode, or total fertility rate [10] (TFR, 6.7 in 2007) are listed
in Table 1. The need for cotrimoxazole (CTX) prophylaxis was
applied to all HIV-exposed children until 18 months of age, to HIV-
infected children under the age of 5 years, as well as to HIV-infected
children 5 years or older and not receiving anti-retroviral therapy
(ART) [17]. The need for ART was defined as all HIV-infected
infants and all children who have progressed to moderate-to-severe
HIV disease [17].
Data analysis
Most data analysis was performed with Spectrum [18] (version
3.3), a demographic projection software with a built-in HIV/AIDS
module; some Spectrum output data were further analyzed using
Microsoft Excel. Using Spectrum, we estimated the actual burden
of pediatric HIV/AIDS for the year 2007 and for the period
from 2008 to 2012 (baseline projection). The primary outcomes
Table 1. Parameters used in analysis.
Dynamic parameters
Year 2007 2008 2012
Total population (millions) [10] 31.5 32.6 37.7
Total fertility rate (live births per woman life) [9,10] 6.7 6.7 6.5
without family planning 8.6 8.6 8.3
w/o unwanted fertility 5.1 5.1 4.9
PMTCT uptake (%), total [8] { 33 39 57
Single dose Nevirapine 31 31 0
Dual ARVs 2 7 48
Triple ARVs 0 1 8
CTX (cotrimoxazole) uptake (pediatric) 25% 30% 50%
No. on ART (pediatric) [28] 8,100 12,300 29,400
Static parameters
Fertility ratio [17] 15–19 yrs. 20–49 yrs. --
HIV-infected:uninfected 1.5 0.47–0.76 --
Breastfeeding [9] Exclusive Mixed Replacement
Distribution by feeding mode 17% 69% 14%
MTCT risk, by feeding and ARV prophylaxis pattern
Perinatal [17,29–31] Postnatal (per month) [17,32]
No prophylaxis 20% ART (taken by mother) 0.3%
Single dose nevirapine 11% Exclusive BF, 1–6 mths 0.8%
Dual ARV 4% Mixed BF, 1–6 mths 1.5%
Triple ARV prophylaxis 2% Mixed BF, 6–36 mths 0.8%
Triple ARV treatment 2% -- --
Annual survival on ART among [17] Infants Children Adults
1st year 85% 85% 86%
Subsequent years N/A 93% 90%
Pediatric mortality reduction due to CTX [17] 33% (First 5 years, w/o ART)
Footnote: Dynamic data reflect mid-year estimates and may thus differ from cited sources. MTCT: Mother-to-child transmission. ARV: anti-retrovirals. ART: anti-retroviral
therapy. BF: Breastfeeding. CTX: cotrimoxazole. N/A: Not applicable.
{For the years 2009–2012, rationale provided in Methods/Data sources.
doi:10.1371/journal.pone.0007691.t001
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examined included the number of incident pediatric HIV
infections, the need for cotrimoxazole and antiretroviral treatment
among HIV-infected children aged 0–14 years, and the number of
AIDS orphans. We then compared this baseline projection to the
following three hypothetical projections: 1) A projection where all
ARV uptake for PMTCT was removed, allowing the estimation of
the number of HIV-positive births (and subsequent events) averted
by ARV prophylaxis. 2) A projection without any FP use, resulting
in the higher TFRc- (no contraceptives) and thereby facilitating
the estimation of the number of (HIV-positive) pregnancies and
subsequent events averted. 3) A projection where all unwanted
fertility was removed, resulting in a lower wTFR (wanted TFR),
thus allowing the estimation of the actual burden of pediatric HIV
disease due to unwanted births. All three hypothetical projections
were identical to the baseline projection until the year 2006. From
2007 onwards, the hypothetical projections differed from the
baseline projection only in the specific alteration described above.
Until the year 2006, all input values were the same for all
projections. From 2007 onwards, input values in the different
projections varied only to the extent described above.TFR,TFRc-,
and wTFR are not specific to the HIV status of women. Based on
UN data [10], TFR was projected to slowly decline until 2012 (by
approximately 3% between 2007 and 2012, Table 1). TFRc- and
wTFR values were both calculated for 2007 using DHS data [9].
To obtain TFRc- and wTFR values for 2008–2012, we applied the
2007 ratio of TFRc-/TFR and wTFR/TFR to the year-specific
TFR values, respectively. Hence the three different fertility rates
remained constant to each other (Figure 1). The difference
between TFRc- and TFR thus indicates the effect of existing
(current) and projected (future) FP use, whereas the difference
between TFR and wTFR indicates the effect of unwanted fertility
( = unmet need for FP). The difference between TFRc- and wTFR
represents the combined total effect of unwanted fertility, partially
realized through existing/projected FP use. To estimate the
combined effect of contraception and ARV-PMTCT, we
compared the baseline projection to a projection where both
contraceptive use and ARV-PMTCT services were removed from
2007 onwards.
Using output data from these projections, we also estimated the
number of events averted for each 1,000 women exposed to ARV-
based PMTCT and/or FP programs. These rates were calculated
as follows: Numerators indicated events averted, as shown in
Table 2; the denominator for FP was calculated as the proportion
of women using FP (CPR 19.6%) times the number of women
aged 15–49 [6.7 million], yielding 1,314,000. For ARV-PMTCT,
the denominator was calculated as the proportion of HIV-infected
pregnant women receiving ARV prophylaxis (estimated as 29.9%)
multiplied by the number of total births (1,529,000), yielding
457,000 women. These proportions were then multiplied by
1,000. In a sensitivity analysis, we estimated the effects of an ARV-
based PMTCT program that would reach the national PMTCT
uptake goal of 80% by 2012 as well as that of a hypothetical FP
program targeting HIV-infected women (leaving CPR unchanged
for HIV-uninfected women), reaching approximately 50% FP use
by 2012. The 50% FP use target represents approximately twice
the proportion of HIV-infected persons who are currently aware of
their serostatus (based on AIS 2004/5 data indicating that
approximately 20% of HIV-infected Ugandan adults had
undergone HIV testing in the past). All numerical estimates were
Figure 1. Fertility projections used in analysis. This figure depicts
the three different fertility scenarios used in analysis, from 2007
onwards. TFRc-: Total fertility rate in the absence of contraceptive use;
TFR (baseline): Current and projected TFR; wTFR: TFR if only wanted
births are considered.
doi:10.1371/journal.pone.0007691.g001
Table 2. Estimated effects of ARV-PMTCT, FP, and unwanted fertility on pediatric HIV, 2007.
Number (%) averted by**)
Number (%) due to
unwanted fertility***
Indicator Total* ARV-PMTCT Family planning
Births (regardless of HIV status) 1,530,000 0 (0.0) 425,000 (21.7) 371,000 (24.3)
HIV-positive pregnancies 105,000 0 (0.0) 29,000 (21.7) 25,000 (23.9)
Vertical HIV infections (incident) 25,000 2,200 (8.1) 6,100 (19.7) 5,300 (21.3)
No. needing CTX prophylaxis 236,000 100 (0.0) 36,000 (13.3) 31,000 (13.2)
No. needing ART 49,000 2,300 (4.5) 5,900 (10.8) 5,100 (10.5)
Pediatric AIDS deaths (2007) 17,000 1,600 (8.5) 2,600 (13.1) 2,300 (13.4)
AIDS orphans (prevalent) 1,521,000 21,800 2(0.1) 1,000 (0.1) 600 (0.0)
Note: *The column ‘‘Total’’ indicates the estimated number of persons in the presence of the actual PMTCT and FP uptake.
**The columns ‘‘ARV-PMTCT’’ and ‘‘Family planning’’ indicate the number of events (person characteristic) that would have occurred in their respective absence.
Negative values denote increases.
***The column ‘‘Number (%) due to unwanted fertility’’ indicates how many events (person characteristic) in the ‘‘Total’’ column are due to unwanted fertility.
Percent estimates: for ARV and existing FP, the denominator comprises the total value plus the averted events; for unwanted fertility, the denominator is given by the
total value. PMTCT: Prevention of mother-to-child transmission; ARV: antiretrovirals; CTX: cotrimoxazole; ART: Anti-retroviral treatment.
doi:10.1371/journal.pone.0007691.t002
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rounded to the nearest 100 (for values ,10,000) or 1,000 (for
values .10,000). All stated ARV-PMTCT uptake figures were
adjusted in the analysis for incomplete ante-natal clinic attendance
(estimated at 92%, using MOH ANC program and Spectrum
projection data for 2007). For the purpose of this analysis, the
terms ‘‘PMTCT’’ and ‘‘ARV-based PMTCT’’ are used synony-
mously unless stated otherwise. We defined children as between 0
and 14 years old, and AIDS orphans as between 0 and 18 years
old who have lost at least one parent due to AIDS. Following DHS
methods, the term ‘‘family planning’’ includes female/male
sterilization, pill, intrauterine devices, injectables, implants,
condoms, lactational amenorrhea, emergency contraception, as
well as the rhythm and withdrawal method or any ‘‘folk method’’
mentioned by the respondent.
Results
2007 estimates
Table 2 shows the results for the year 2007 when an estimated
1,530,000 births occurred. ARV-PMTCT (2007 uptake: 33%) has
no measurable effect on the number of HIV-positive pregnancies
occurring in Uganda. Existing FP use likely averted an additional
425,000 births including 29,000 HIV-positive pregnancies whereas
unwanted fertility resulted in an estimated 25,000 HIV-positive
pregnancies. Approximately 25,000 vertical HIV infections occurred
in the presence of the existing FP use and ARV-PMTCT program.
PMTCT averted some 8.1% of vertical infections, FP 19.7%, and
unwanted fertility accounted for 21.3%. ARV-PMTCT had no
substantial effect on the number of HIV-exposed infants needing
CTX prophylaxis that same year. FP use reduced the need for CTX
prophylaxis by 13.3%; unwanted fertility accounted for a similar
proportion. ARV-based PMTCT reduced the number of children
requiring ART and the number of AIDS deaths by an estimated
4.5% and 8.5%, respectively. In addition, FP use averted 10.8% and
13.1%, respectively, while unwanted fertility accounted for similar
proportions. By keeping more children HIV-uninfected and
surviving their HIV-infected mothers, ARV-PMTCT slightly
increases the number of AIDS orphans.
2008–2012 estimates
Table 3 shows estimates for 2008–2012. During this 5-year
period, projected contraceptive use (held stable) is likely to avert
approximately 2.4 million births (of any HIV-status); in contrast,
unwanted fertility may lead to slightly more than 2 million births.
FP use may reduce HIV-positive pregnancies by 22% whereas
unwanted fertility is likely to account for almost a quarter of all
HIV-positive pregnancies in antenatal care. Compared with 2007,
the increase in ARV uptake for PMTCT (from 33% to 57%) and
the switch to more efficacious ARV regimens likely will
substantially increase the proportion of vertical infections averted
(from 8.1% to 18.1%). In comparison, FP use is projected to avert
21.6% of vertical infections whereas unmet FP needs may be
responsible for 24.5% of infections, i.e., the met and unmet FP
needs combined correspond to 46% of vertical infections. By 2012,
the scale up of ARV-PMTCT may avert 24.1% of vertical
infections, still falling short of its goal to reduce MTCT by 50%.
However, adding existing FP use, which by itself is projected to
avert 21.6% of MTCT, together with ARV-PMTCT may avert
40.6% (separate analysis, data not shown) of MTCT, and
addressing unmet FP needs would help surpass this goal.
Large differences were observed in the effect of ARV-based
PMTCT and FP on care and treatment needs expressed as PY
(person-years, Table 3). From 2008–2012, PMTCT will mitigate
the estimated need for pediatric CTX prophylaxis and ART by
1% and 12.2% respectively; FP use will reduce these needs by an
estimated 15.9% and 13.1%, respectively, and whereas unmet FP
needs are responsible for an estimated 16.5% and 13.2%,
respectively. ARV-PMTCT may substantially reduce pediatric
AIDS deaths (24.5%), more than the met (18.5%) or unmet
(19.8%) FP needs will likely reduce or account for. As in 2007, the
survival benefit of HIV-exposed newborns provided through
ARV-PMTCT continues to paradoxically increase the number of
AIDS orphans marginally by 0.3% in 2008 and 1.5% in 2012. FP
use probably leads to a small decrease in AIDS orphan years
(1.2%, 2008-12).
Sensitivity analysis
Table 4 shows the hypothetical achievements of an ARV-
PMTCT program scaled up to reach 80% uptake by 2012 as well
as the potential effects of FP use by 50% of all HIV-infected
women aged 15–49 years. Table 5 restricts the results to the last
year of the scale-up. In this scenario, the number of vertical
infections averted remain below Uganda’s goal of preventing 50%
of all MTCT-related HIV infections through ARV-PMTCT
(Table 5). However, adding the effects of projected FP use (as
shown in Table 3) would avert approximately 46% of MTCT,
close to the stated goal. Conversely, by focusing FP services on
HIV-infected women (50% FP use) together with the more
realistic ARV-PMTCT scale up scenario reaching 57% uptake
these two interventions combined are estimated to avert 54% of all
MTCT in 2012.
Table 3. Estimated effects of ARV-PMTCT, FP, and unwanted fertility on pediatric HIV, 2008–2012.
Number (%) averted by
Number (%) due to
unwanted fertility
Indicator Total ARV-PMTCT Family planning
Births (regardless of HIV status) 8,475,000 0 (0.0) 2,353,000 (21.7) 2,053,000 (24.2)
HIV-positive pregnancies 617,000 0 (0.0) 171,000 (21.7) 149,000 (24.2)
Vertical HIV infections (incident) 131,000 29,000 (18.1) 36,000 (21.6) 32,000 (24.5)
Children needing CTX prophylaxis (PY) 1,226,000 12,000 (1.0) 232,000 (15.9) 202,000 (16.5)
Children needing ART (PY) 266,000 37,000 (12.2) 40,000 (13.1) 35,000 (13.2)
Pediatric AIDS deaths 71,000 23,000 (24.5) 16,000 (18.5) 14,000 (19.8)
AIDS orphans (PY) 6,877,000 255,000 2(0.8) 81,000 (1.2) 67,000 (1.0)
Note: PY: person-years. CTX: cotrimoxazole.
doi:10.1371/journal.pone.0007691.t003
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Events averted per 1000 women exposed to ARV-PMTCT
or FP
As outlined in the Methods section, we also examined the
separate impact of ARV-PMTCT and FP as expressed per 1,000
women exposed to either service; results are shown in Table 6.
Both interventions are similarly effective in averting vertical
infections although substantial differences can be observed for
other indicators.
Discussion
Every day in Uganda, FP averts approximately 20 vertical
infections and 9 pediatric AIDS deaths. Our comparative
analysis suggests that existing FP services significantly contribute
to the goals of PMTCT in Uganda, exceeding the current
achievements of ARV-PMTCT alone. Even the projected
expansion of ARV uptake (in scale and quality) from 2008–
2012 is matched by the effects of projected use of FP. At the same
time, unwanted fertility in Uganda accounts for a substantial
amount of pediatric HIV disease and will continue to do so unless
access to FP services improves significantly. Targeting FP services
for HIV-infected women could have a dramatic positive effect for
PMTCT.
Our estimates’ validity depends on the underlying formulas used
in Spectrum as well as on the validity of the input data and
underlying assumptions, such as MTCT probabilities or ARV-
PMTCT uptake. The Spectrum software is reviewed by the
UNAIDS Reference Group on Estimates, Models and Projections
to ensure that it uses the latest data, recreates the pattern of
historical epidemics and is consistent with other data sources such
as estimates of AIDS mortality [19], the number of orphans and
vulnerable children [20], and the number in need of ART [21].
Most assumptions were adopted from the Spectrum software’s
default values which are based on review of international literature
by expert panels. Although ante-natal clinic based HIV prevalence
estimates have to be interpreted with caution [22], our estimates
mainly rely on a national population-based HIV survey. We kept
HIV prevalence stable over time as no new national estimates
were available for the years after 2005. Although changes in HIV
prevalence would affect the absolute size of estimates (e.g., number
of vertical infections), they would have little impact on the relative
effects (e.g., proportion of vertical infections averted) of ARV-
PMTCT or FP and hence would not change the overall findings
and conclusions. TFR was allowed to decline very slowly (as
projected by the United Nations) whereas the uptake of
combination ARVs steadily rose. The effect of ARV-PMTCT is
particularly sensitive to its projected uptake until 2012. As
mentioned, we chose a modest but realistic increase in ARV-
PMTCT uptake and addressed the international goal of universal
PMTCT coverage (corresponding to 80% uptake) in the context of
a sensitivity analysis. This is because in order to meet Uganda’s
programmatic goals (including a reduction of vertical infections by
Table 4. Estimated effects of a 80% ARV-PMTCT uptake or 50% FP use among HIV-infected women, 2008–2012.
Number (%) avertable by intervention**
Indicator Total* ARV-PMTCT FP use
HIV-positive pregnancies 617,000 0 (0.0) 268,000 (34.0)
Vertical HIV infections (incident) 131,000 38,000 (23.8) 55,000 (32.9)
Children needing CTX prophylaxis (PY) 1,226,000 16,000 (1.3) 341,000 (23.4)
Children needing ART (PY) 266,000 49,000 (16.2) 59,000 (19.2)
Pediatric AIDS deaths 71,000 30,000 (32.1) 24,000 (27.0)
AIDS orphans (PY) 6,877,000 266,000 2(1.0) 53,000 (0.8)
Note: *The column ‘‘Total’’ estimates the number of events or person years as given by the baseline projection, in the presence of the actual estimated uptake of ARV-
PMTCT and FP.
**The columns ‘‘ARV-PMTCT’’ and ‘‘FP use’’ indicate the number of events (person characteristic) that would occur in addition in their respective absence. Negative
values denote increases.
Percent estimates: the denominator is give by the number in the absence of the intervention; the numerator indicates the number of events averted. CTX:
cotrimoxazole. PY: person-years. FP: Family planning. 80% ARV-PMTCT uptake and 50% FP use (among HIV+ women) are scaled up beginning 2009 and reach their goals
by 2012.
doi:10.1371/journal.pone.0007691.t004
Table 5. Estimated effects of a 80% ARV-PMTCT uptake or 50% FP use among HIV-infected women, by 2012.
Number (%) avertable by intervention
Indicator Total ARV-PMTCT FP use
HIV-positive pregnancies 135,000 0 (0.0) 78,000 (45.2)
Vertical HIV infections (incident) 26,000 12,000 (34.4) 15,000 (44.3)
Children needing CTX prophylaxis 254,000 7,000 (2.7) 102,000 (32.8)
Children needing ART 57,000 16,000 (23.3) 17,000 (25.4)
Pediatric AIDS deaths 12,000 9,000 (47.6) 6,200 (39.7)
AIDS orphans 1,280,000 225,000 2(2.0) 26,000 (2.0)
Note: All values shown apply to the year 2012 only.
doi:10.1371/journal.pone.0007691.t005
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50% in 2011/2012 compared to 2006/2007), its national strategic
plan [5] for 2007–2012 calls for more than a three-fold increase in
financial resources. Instead we chose what we thought to be a
feasible increase in ARV-PMTCT uptake in an essentially flat
funding environment for the foreseeable future. Changes in these
and other parameters all affect the outcomes shown here although
they would not alter the main conclusions. The inputed MTCT
probabilities reflect findings from various trial data, implying that
program effectiveness equals trial efficacies. PMTCT reports from
Uganda however indicate that perhaps half of HIV-exposed
newborns miss taking ARVs for PMTCT even though their
mothers receive them [8], a factor we could not account for in our
projections. Finally, better national data on FP service provision,
access, and use, as well as TFR, childbearing desires, unintended
pregnancies, and induced abortions among women at risk for or
infected with HIV would have allowed a more refined analysis and
a more informed discussion. Hopefully, such data will be become
available in the future.
Our analysis on the effects of FP was limited to those relevant
for pediatric HIV from 2007–2012. Because we left TFRc- and
wTFR projections unchanged for historical years, we did not
consider the effect of past contraceptive use or non-use (prior to
2007) on the current or future burden of pediatric HIV/AIDS.
In fact, since the start of Uganda’s HIV epidemic (assumed to be
in 1980), contraceptive use likely averted a cumulative total of
280,000 vertical HIV infections and 180,000 pediatric AIDS
deaths, while unwanted fertility led to 220,000 vertical infections
and 140,000 pediatric AIDS deaths until 2009 (separate
analysis, data not shown). We also did not consider other well
described non HIV-specific benefits of FP such as improvement
in gender inequality and female empowerment, reduction
in overall child and maternal mortality, improving maternal
health, as well as (indirectly) mitigating poverty, hunger, and
facilitating universal primary education [23]. Neither did we
consider mistimed births, i.e., births occurring earlier than
desired and easily avertable by family planning and part of the
larger group of unintended pregnancies. Improved access to
family planning would likely reduce the high maternal mortality
(estimated at 550/100,000 live births [24]) and abortion rate in
Uganda, estimated at 54 per 1,000 women [25], translating into
approximately 300,000 abortions per year, or one in five
pregnancies. Elective abortions are illegal in Uganda [25], and
thus are often carried out informally with greater risk for the
mother.
The contribution of family planning for PMTCT gained
substantial momentum in the literature in this decade [11,13–
15,26,27]. Reynolds et al. [11] recently analyzed this topic for
countries receiving funds from the United States PEPFAR
(President’s Emergency Plan For AIDS Relief) program, including
Uganda, with similar conclusions as in our analysis.
The timing of events leading to an HIV-infected child (HIV
acquisition by a woman of reproductive age, followed by
pregnancy and subsequent MTCT), makes it clear that family
planning for PMTCT is entirely complementary to ARV-based
PMTCT. Because family planning precedes ARV-based PMTCT
in sequential order, reducing unwanted pregnancies alleviates the
resource-intensive ante-natal clinic and ARV-based PMTCT
services. Uganda’s CPR (contraceptive prevalence rate) is
estimated at just 19.6% [9] including traditional methods (4.1%);
a CPR increase to 34% (or 41% among currently married women)
is necessary to reach the total wanted fertility rate of 5.1 that was
used in this analysis. Most HIV-infected Ugandan women of
reproductive age are unaware of their HIV status and many would
opt for FP if they knew their serostatus or had better access to FP.
An immediate and targeted measure calls for better – real –
integration of FP services into post-natal care for HIV-positive and
indeed all sexually active women of reproductive age. However,
PMTCT funds have not been available for this purpose in Uganda
[8], not least as some donors do not allow for the procurement of
family planning commodities. PMTCT training curricula need to
address all four PMTCT pillars as should monitoring and
evaluation programs reviewing PMTCT services. Voluntary
counseling and testing programs actively offering FP services to
HIV-infected adults would avert many subsequent unwanted
HIV-positive pregnancies. Moreover, given the risk of HIV
transmission associated with unprotected sex, the promotion of
dual family planning (the combined use of a barrier with a
hormonal FP method) would achieve reductions in both vertical
and horizontal HIV infections. Lastly, a general investment to
expand FP services for all sexually active persons may yield the
broadest benefits for HIV-positive and negative women alike,
averting transmission in HIV-discordant relationships and unin-
tended pregnancies (irrespective of HIV status) and its many
consequences.
Even the planned expansion of ARV-PMTCT uptake to 80% by
itself is unlikely to achieve Uganda’s goal to reduce MTCT by 50%
[5]. Comprehensive PMTCT that includes both ARV prophylaxis
and FP services is needed to make such goals achievable. Modern
FP methods are safe, cost-effective [11,13–15], and provide
substantial benefits towards PMTCT and beyond. These data
demonstrate the substantial potential benefit of increasing FP
coverage on reducing HIV infections in children in Uganda. Better
integration of FP with PMTCT programs would be an important
way to achieve this benefit. Donors, policy makers, and program
planners need to acknowledge and embrace the real contribution of
FP for PMTCT and support its expansion.
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Table 6. Pediatric events averted annually for each 1000
women (any HIV status) utilizing either PMTCT or FP services.
PMTCT FP
Births (regardless of HIV status) 0.0 323.4
HIV-positive pregnancies 0.0 22.1
Vertical HIV infections 4.8 4.6
Children needing CTX prophylaxis 0.2 27.4
Children needing ART 5.0 4.5
Pediatric AIDS deaths 3.5 2.0
AIDS orphans 23.9 0.8
Note: Data pertain to the year 2007. Negative numbers indicate increases.
PMTCT: Prevention of mother-to-child transmission; FP: Family planning; CTX:
Cotrimoxazole; ART: Antiretroviral therapy.
doi:10.1371/journal.pone.0007691.t006
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